Therapeutic potential of oncolytic measles virus: promises and challenges.
Measles virus (MV) is a negative-strand RNA virus (paramyxovirus) with oncolytic properties. The significant preclinical activity of MV vaccine strains against a variety of tumor models, their potent bystander effect, their selectivity against tumor cells, and their ability to retain their oncolytic properties when engineered and retargeted makes them a promising oncolytic platform. In this article, we review potential applications and challenges associated with use of MV strains as cancer therapeutics.
Galanis
E
E
Departments of Oncology and Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA. galanis.evanthia@mayo.edu
D000818:Animals; D004195:Disease Models, Animal; D015967:Gene Expression Regulation, Viral; D006801:Humans; D008459:Measles virus / Q000235:genetics / Q000276:immunology / Q000472:pathogenicity*; D009369:Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D050130:Oncolytic Virotherapy; D050504:Oncolytic Viruses / Q000235:genetics / Q000276:immunology / Q000472:pathogenicity*; D016896:Treatment Outcome